596 results found
Ramagopalan S, Popat S, Gupta A, et al., 2022, Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment, JAMA NETWORK OPEN, Vol: 5, ISSN: 2574-3805
Fendler A, Shepherd STC, Au L, et al., 2022, Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer, Cell Reports Medicine, Vol: 3, ISSN: 2666-3791
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
O'Sullivan H, d'Arienzo PD, Yousaf N, et al., 2022, Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla (TM) EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib' Not looking back, EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: 318-320, ISSN: 0959-8049
Cho BC, Lin J, Camidge DR, et al., 2022, Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+advanced non-small cell lung cancer (NSCLC), EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: S1-S2, ISSN: 0959-8049
Besse B, Springfeld C, Baik C, et al., 2022, Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naive and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1), EUROPEAN JOURNAL OF CANCER, Vol: 174, Pages: S75-S76, ISSN: 0959-8049
Zhang YZ, Sherlock S, Brambilla C, et al., 2022, Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases, Publisher: ELSEVIER SCIENCE INC, Pages: S516-S517, ISSN: 1556-0864
Zhang YZ, Nicholson AG, Ly F, et al., 2022, Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave), Publisher: ELSEVIER SCIENCE INC, Pages: S112-S114, ISSN: 1556-0864
O'Sullivan HM, MacMahon S, Cui W, et al., 2022, Frequency and Detectability of Uncommon EGFR Mutations in NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S88-S89, ISSN: 1556-0864
Garcia Campelo MR, Zhou C, Ramalingam SS, et al., 2022, PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC), Publisher: ELSEVIER SCIENCE INC, Pages: S487-S488, ISSN: 1556-0864
Eastwood M, Marc ST, Gao X, et al., 2022, MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images, Publisher: ELSEVIER SCIENCE INC, Pages: S331-S332, ISSN: 1556-0864
O'Sullivan HM, MacMahon S, Cunningham N, et al., 2022, Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations, Publisher: ELSEVIER SCIENCE INC, Pages: S430-S430, ISSN: 1556-0864
Begum P, O'Sullvan H, D'Arienzo P, et al., 2022, Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S461-S462, ISSN: 1556-0864
McDonald F, Guckenberger M, Popat S, et al., 2022, HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours, Publisher: ELSEVIER SCIENCE INC, Pages: S492-S492, ISSN: 1556-0864
Griesinger F, Camidge DR, Kim HR, et al., 2022, Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC), Publisher: KARGER, Pages: 103-104, ISSN: 2296-5270
Begum P, Cui W, Popat S, 2022, Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report., JTO Clin Res Rep, Vol: 3
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
Paz-Ares LG, Ciuleanu T-E, Pluzanski A, et al., 2022, Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817., J Thorac Oncol
INTRODUCTION: We characterized the safety of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large patient population with metastatic NSCLC and efficacy outcomes after NIVO+IPI discontinuation owing to treatment-related adverse events (TRAEs). METHODS: We pooled data from three first-line NIVO+IPI studies (NIVO, 3 mg/kg or 240 mg every 2 wk; IPI, 1 mg/kg every 6 wk) in metastatic NSCLC (CheckMate 227 part 1, CheckMate 817 cohort A, CheckMate 568 part 1). Safety end points included TRAEs and immune-mediated adverse events (IMAEs) in the pooled population and patients aged 75 years or older. RESULTS: In the pooled population (N = 1255), any-grade TRAEs occurred in 78% of the patients, grade 3 or 4 TRAEs in 34%, and discontinuation of any regimen component owing to TRAEs in 21%. The most frequent TRAE and IMAE were diarrhea (20%; grade 3 or 4, 2%) and rash (17%; grade 3 or 4, 3%), respectively. The most common grade 3 or 4 IMAEs were hepatitis (5%) and diarrhea/colitis and pneumonitis (4% each). Pneumonitis was the most common cause of treatment-related death (5 of 16). Safety in patients aged 75 years or older (n = 174) was generally similar to the overall population, but discontinuation of any regimen component owing to TRAEs was more common (29%). In patients discontinuing NIVO+IPI owing to TRAEs (n = 225), 3-year overall survival was 50% (95% confidence interval: 42.6-56.0), and 42% (31.2-52.4) of 130 responders remained in response 2 years after discontinuation. CONCLUSIONS: First-line NIVO+IPI was well tolerated in this large population with metastatic NSCLC and in patients aged 75 years or older. Discontinuation owing to TRAEs did not reduce long-term survival.
Cui W, Milner-Watts C, O'Sullivan H, et al., 2022, Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients, EUROPEAN JOURNAL OF CANCER, Vol: 171, Pages: 44-54, ISSN: 0959-8049
Pascual J, Attard G, Bidard F-C, et al., 2022, ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group., Ann Oncol, Vol: 33, Pages: 750-768
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society for Medical Oncology convened an expert working group to review the analytical and clinical validity and utility of ctDNA assays. For patients with advanced cancer, validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, and may be used in routine clinical practice, provided the limitations of the assays are taken into account. Tissue-based testing remains the preferred test for many cancer patients, due to limitations of ctDNA assays detecting fusion events and copy number changes, although ctDNA assays may be routinely used when faster results will be clinically important, or when tissue biopsies are not possible or inappropriate. Reflex tumour testing should be considered following a non-informative ctDNA result, due to false-negative results with ctDNA testing. In patients treated for early-stage cancers, detection of molecular residual disease or molecular relapse, has high evidence of clinical validity in anticipating future relapse in many cancers. Molecular residual disease/molecular relapse detection cannot be recommended in routine clinical practice, as currently there is no evidence for clinical utility in directing treatment. Additional potential applications of ctDNA assays, under research development and not recommended for routine practice, include identifying patients not responding to therapy with early dynamic changes in ctDNA levels, monitoring therapy for the development of resistance mutations before clinical progression, and in screening asymptomatic people for cancer. Recommendations for reporting of results, future development of ctDNA assays and future clinical research are made.
Reckamp KL, Lin HM, Cranmer H, et al., 2022, Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L, CURRENT MEDICAL RESEARCH AND OPINION, Vol: 38, Pages: 1587-1593, ISSN: 0300-7995
Ahn MJ, Kim HR, Yang JCH, et al., 2022, Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study., Clin Lung Cancer
BACKGROUND: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. PATIENTS AND METHODS: This was a subgroup analysis from the phase III ALTA-1L trial of brigatinib vs. crizotinib in ALK inhibitor-naive ALK+ NSCLC. The primary endpoint was progression-free survival (PFS) as assessed by blinded independent review committee (BIRC). Secondary endpoints included confirmed objective response rate (ORR) and overall survival (OS) in the overall population and BIRC-assessed intracranial ORR and PFS in patients with brain metastases. RESULTS: Of the 275 randomized patients, 108 were Asian. Brigatinib showed consistent superiority in BIRC-assessed PFS vs. crizotinib in Asian (hazard ratio [HR]: 0.35 [95% CI: 0.20-0.59]; log-rank P = .0001; median 24.0 vs. 11.1 months) and non-Asian (HR: 0.56 [95% CI: 0.38-0.84]; log-rank P = .0041; median 24.7 vs. 9.4 months) patients. Results were consistent with investigator-assessed PFS and BIRC-assessed intracranial PFS. Brigatinib was well tolerated. Toxicity profiles and dose modification rates were similar between Asian and non-Asian patients. CONCLUSION: Efficacy with brigatinib was consistently better than with crizotinib in Asian and non-Asian patients with locally advanced or metastatic ALK inhibitor-naive ALK-+ NSCLC. There were no clinically notable differences in overall safety in Asian vs. non-Asian patients.
Banna GL, Addeo A, Zygoura P, et al., 2022, A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial, LUNG CANCER, Vol: 169, Pages: 77-83, ISSN: 0169-5002
Miura S, Jung HA, Lee SY, et al., 2022, Sequential afatinib and osimertinib in Asians with EGFRm plus NSCLC: combined analysis of two non-interventional studies, 19th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO), Publisher: ELSEVIER, Pages: S501-S501, ISSN: 0923-7534
Miura S, Schuler M, Popat S, et al., 2022, A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib: focus on Asian patients, 19th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO), Publisher: ELSEVIER, Pages: S500-S500, ISSN: 0923-7534
Popat S, Liu SV, Scheuer N, et al., 2022, Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer, NATURE COMMUNICATIONS, Vol: 13
Aguilar-Duran S, Mee J, Popat S, et al., 2022, Atezolizumab-induced linear IgA bullous dermatosis, BRITISH JOURNAL OF DERMATOLOGY, ISSN: 0007-0963
Aravind P, Popat S, Barwick TD, et al., 2022, [F-18]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed., Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Coker EA, Stewart A, Ozer B, et al., 2022, Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes, MOLECULAR CANCER THERAPEUTICS, Vol: 21, Pages: 1020-1029, ISSN: 1535-7163
Zauderer MG, Szlosarek PW, Le Moulec S, et al., 2022, EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study, LANCET ONCOLOGY, Vol: 23, Pages: 758-767, ISSN: 1470-2045
Camidge DR, Kim HR, Ahn M-J, et al., 2022, Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK plus NSCLC in ALTA-1L., Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
Popat S, Felip E, Kim ES, et al., 2022, AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion-positive advanced/metastatic NSCLC., Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.